We dedicate this month’s issue to Asia.


a&r at Vitafoods Asia

For the first time, a&r will attend Vitafoods Asia, the only nutraceuticals event of this type in Asia. The event will be held in Hong Kong from 1st to 2nd of September 2016 at the AsiaWorld-Expo. A brief description of a&r presentations is presented below.

  1. Asian market – Opportunities for Growth (Dr. Volker Spitzer): Due to the lack of response to the rising of chronic and lifestyle-related diseases in Asia, consumers are taking a proactive approach for their prevention. Thus, there is a need for innovative and meaningful solutions from the nutraceutical, dietary supplement, and functional food industries. Which are the main health concerns? What is the innovation landscape? Which are the gaps and opportunities for this industry in Asia?
  2. Innovation and Best Practice in Alternative Delivery Options (Dr. Volker Spitzer): Innovation has been a key factor for differentiation between brands and products focusing more on consumer needs and desires. The line between the classical medical approach and food products is getting thinner, giving companies a new range of opportunities. Which is the current delivery formats? Which are the opportunities and limitations for delivery formats? How do consumer preferences change within different regions?
  3. EU Market Access (Dr. Iris Hardewig): Highly attractive innovative products are being developed outside of the European Union (EU). How can these products gain access to the EU markets? The presentation will provide a first guidance on how to overcome some major challenges within the EU in order to successfully market products from the Asian region in the EU, and discuss examples of successful launches of Asian products in EU markets.

a&r comments: This is an important event for the nutraceutical industry as it affords the opportunity to source ingredients, raw materials, dietary supplements, and services all in one place. From next year onwards, Vitafoods Asia will be held in Singapore.

New approaches

TCM in Europe: First Chinese Herbal Medicine trial in the UK

Antimicrobial resistance is a major problem in western countries. Since the end of May this year, GPs in the UK have been involved in directly administering Chinese Herbal Medicines to patients with recurrent urinary tract infections (UTIs). This two-arm, double blind, randomized, placebo controlled trial for recurrent UTIs is sponsored by the University of Southampton, along with the support of the National Institute for Health Research. 80 women recruited by GPs have two optional lines of treatment. They either receive an “individualized” treatment by a Chinese practitioner, or a “standardized” herb provided by the primary care clinician for 16 weeks. The study aims to assess weather herbal medicines could play an important role in replacing some antibiotic treatments for specific conditions.

a&r comments: This is a first for Chinese medicine in the UK. Until this date, no other clinical trial of this nature has been authorized. The increased antimicrobial resistance raises the need for new approaches to infection management and antibiotic prescription. Herbal medicines can play a big role in common infections such as UTIs, sore throat, and acute cough. Moreover, Chinese herbal medicine has a long tradition of treating symptoms of UTIs.


Asian research on Pre- and Probiotics

Growing awareness of the health benefits generated by probiotics is driving global growth in this vibrant market. The Asia-Pacific probiotic market leads the global industry with an anticipated five-year CAGR of 8.3%.

Potentially driven by their long tradition of using fermented foods (e.g. fermented kimchi), Asia is one of the epicenters of probiotic research. Regarding prebiotics, a Chinese research group isolated two polysaccharides (WBP-1 and WBP-2) from bamboo shoots (Phyllostachys praecox) that might have the potential to be used as functional ingredients. These two polysaccharides have significantly increased the number of two strains of Bifidobacterium, suggesting their prebiotic properties.

On the probiotic side, a Joint Center for probiotic research has been created between Jiangnan University in China and UK’s Institute of Food Research (IFR). This collaboration aims to address the challenges facing both countries in the probiotic arena such as the development of probiotics that can help tackle antimicrobial resistance. Also demonstrating this ongoing trend, the Family Planning and National Health Commission of the People’s Republic of China granted to the Spanish biotechnology firm “Biosearch Life” authorization to use its probiotic Lactobacillus fermentum CECT5716 LC40 (LC40 strain), which is isolated from breast milk, in infant formula. The strain is already in use in children’s nutrition products in Europe.

A recent meta-analysis from a Chinese research group showed that taking probiotics reduced BMI and body weight mainly in adults. The study included data from 25 randomized clinical trials assessing the impact of probiotic consumption on body weight and BMI in more than 1,900 people over the age of 18 years. While the impact of the reduction was low (reduction of 0.59 kg of body weight and 0.49 kg/m2 BMI in average), greater reductions were observed in specific subgroup analyses such as in trials with multiple species of probiotics used, or in longer intervention studies. These findings suggest new possibilities in the field of overweight and obesity.

a&r comments: An improvement of the cooperation between Asian and Western research groups on natural health products will lead to improved and innovative products in the field of pre- and probiotics, with extreme benefit for Asia as well as Western markets.

French tax reduction

The French Ministère de l’Education Nationale de l’Enseignement Supérieur et de la Recherche confirmed that French clients for R&D services rendered by a&r are eligible for tax relief.

Le Ministère de l’Education Nationale de l’Enseignement Supérieur et de la Recherche a confirmé que les clients d’a&r – dans le domaine de la Recherche et du Développement (R&D) – peuvent désormais bénéficier du Crédit d’Impôt Recherche (CIR).

Hope to see you soon!

analyze realize news digest july 2016

Vitafoods Asia – 1-2 September 2016, Hong Kong

5th Supplement Claims workshop – 30 September 2016, Brussels

Bildschirmfoto 2016-08-25 um 12.00.27

CPhI Worldwide – 4-6 October 2016, Barcelona


SupplySide West – 4-8 October 2016, Las Vegas

Your experts

Irene Wohlfahrt
Irene WohlfahrtSenior Consultant
Dr. Inês Rocha
Dr. Inês RochaScientific Consultant

At analyze & realize, we are experts in the field of natural health products, having provided our services for more than 20 years. We offer a unique combination of expertise in natural health products through our scientific, regulatory, and strategic innovation consulting and our clinical research organization with its own clinical trial center in Berlin, Germany. Thanks to our close interaction with the natural product market as well as our extensive network, we are always at the forefront of the latest information and innovation trends. With its international team of 35 employees, a&r is a leading European one-stop-shop ready to guide and support your needs in natural health product innovation.

Don’t hesitate to contact us: newsletter@a-r.com